All In Biotech

Drug Trial Radar · NCT05664152

An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

An Open-label, Bridging Study to Assess the Safety and Immunogenicity of BARYCELA Inj. (Live Attenuated Varicella Vaccine for Injection) in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

Last checked: Nov 19, 2026Latest source record: Dec 23, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

250

Planned (sponsor's estimate)

Start

Feb 2023

Primary completion

Apr 2023

Study completion Jun 2023

Sponsor

Lead sponsor
GC Biopharma CorpIndustry
Sponsor type
Industry
First posted
Dec 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 12 months, up to 12 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The goal of this bridging study is to assess the safety and immunogenicity of BARYCELA inj. in healthy Vietnamese children aged between 12 months to 12 years. The main questions it aims to answer are: * Safety of BARYCELA inj. (Live attenuated varicella vaccine for injection) * Immunogenicity of BARYCELA inj. (Live attenuated varicella vaccine for injection) Participants will be administered subcutaneously with a single dose(0.5 mL dose) of the BARYCELA inj.(MG1111) on the upper arm (brachia lateral).

Conditions

  • Varicella Zoster Virus Infection

Interventions

  • MG1111Biological

    BARYCELA inj.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety of BARYCELA inj.: Solicited local and systemic reactogenicityTime frame: within 30-minute post vaccination
  2. Safety of BARYCELA inj.: The incidence and severity of solicited local and systemic AEsTime frame: during 7 days post vaccination
  3. Safety of BARYCELA inj.: Incidence and severity of unsolicited AEsTime frame: during 42 days post vaccination
  4. Safety of BARYCELA inj.: Incidence of adverse event of special interestTime frame: during 42 days post vaccination
  5. Safety of BARYCELA inj.: Vital signsTime frame: Day0(Pre vaccination), 42 days post vaccination
  6. Safety of BARYCELA inj.: Body temperatureTime frame: Day0(Pre vaccination), 42 days post vaccination
  7. Safety of BARYCELA inj.: Complete physical examinationTime frame: Day0(Pre vaccination), 42 days post vaccination
  8. Safety of BARYCELA inj.: Symptom-directed physical examinationTime frame: Day0(Pre vaccination), during 42 days post vaccination

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.